Sangon Biotech: difference between revisions
Diff·revision 11 → 12·03:19, 23 Apr 2025
Difference between revision 11 and revision 12 of Sangon Biotech. 2 lines changed; the page grew by 512 bytes.
| Revision 11 — 09:08, 9 Apr 2025 UnderfillUna (talk) expand §Notability and coverage 6,911 bytes +144 | Revision 12 — 03:19, 23 Apr 2025 ArchiveBot (talk) bot: add supplier category 7,423 bytes +512 | ||
|---|---|---|---|
| 52 | Submitted reports on SGN peptide material to July 2026 are moderate in number. Reported [[Area percent purity|area percent]] figures have been high and consistent with accompanying certificates.{{r|reports}} | 52 | Submitted reports on SGN peptide material to July 2026 are moderate in number. Reported [[Area percent purity|area percent]] figures have been high and consistent with accompanying certificates.{{r|reports}} |
| 53 | 53 | ||
| + | 54 | Because the reagent business operates in a market with its own documentation conventions, purchasers have been able to compare two documentary traditions on one supplier's paperwork: specification sheets and lot certificates on the reagent side, batch certificates on the peptide side.{{r|reports}} That comparison sits within a single organisation and is therefore more informative than a comparison across organisations. Both traditions identify the lot, which is what makes either document checkable at all. | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |